Detection and cultivation of circulating tumor cells in malignant pleural mesothelioma

Anticancer Research

Volumn 34, Issue 5, 2014, Pages 2565-2570

  Bobek, Vladimir ^a,b,c   Kacprzak, Grzegorz ^d   Rzechonek, Adam ^d   Kolostova, Katarina ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

^b CHARLES UNIVERSITY   (Czech Republic)

^c WROCLAW MEDICAL UNIVERSITY   (Poland)

^d Department of Thoracic Surgery of Lower Silesian Centre ^*  (Poland)

Author keywords

Circulating tumor cells; CTC; Cultivation; Mesothelioma; MetaCell

Indexed keywords

POLYCARBONATE;

ADULT; AGED; ARTICLE; CANCER CELL CULTURE; CANCER DIAGNOSIS; CELL SEPARATION; CIRCULATING TUMOR CELL; CLINICAL ARTICLE; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; MALE; METACELL; MIDDLE AGED; PLEURA MESOTHELIOMA; SEPARATION TECHNIQUE; TUMOR VOLUME; BLOOD; CTC; CULTIVATION; LUNG TUMOR; MESOTHELIOMA; METHODOLOGY; PATHOLOGY; PLEURA TUMOR; TUMOR EMBOLISM;

CIRCULATING TUMOR CELLS; CTC; CULTIVATION; MESOTHELIOMA; METACELL;

AGED; CELL SEPARATION; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MESOTHELIOMA; MIDDLE AGED; NEOPLASTIC CELLS, CIRCULATING; PLEURAL NEOPLASMS;

EID: 84903220181     PISSN: 02507005     EISSN: 17917530     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Ray M and Kindler HL: Malignant pleural mesothelioma: an update on biomarkers and treatment. Chest 136: 888-896, 2009.
2. Tomasetti M and Santarelli L: Biomarkers for Early Detection of Malignant Mesothelioma: Diagnostic and Therapeutic Application. Cancers 2: 523-548, 2010.
3. Scherpereel A and Lee YCG: Biomarkers for mesothelioma. Curr Opin Pulm Med 13: 339-343, 2007.
4. Hartge P: Designing early detection programs for ovarian cancer. J Natl Cancer Inst 102: 3-4, 2010.
5. Johnston FM, Tan MC, Tan BR, Porembka MR, Brunt EM, Linehan DC, Simon PO, Plambeck-Suess S, Eberlein TJ, Hellstrom KE, Hellstrom I, Hawkins WG and Goedegebuure P. Circulating mesothelin protein and cellular antimesothelin immunity in patiens with pancreatic cancer. Clin Cancer Res 15: 6511-6518, 2009.
6. Pass HI, Lott D, Lonardo F, Harbut M, Liu Z, Tang N, Carbone M, Webb C and Wali A: Asbestos exposure, pleural mesothelioma, and serum osteopontin levels. N Engl J Med 353: 1564-1573, 2005.
7. Renshaw AA, Dean BR, Antman KH, Sugarbaker DJ and Cibas ES: The role of cytological evaluation of pleural fluid in the diagnosis of malignant mesothelioma. Chest 111: 106-109, 1997.
8. Zielinski M, Hauer J, Hauer L, Pankowski J, Nabialek T and Szlubowski A: Staging algorithm for diffuse malignant pleural mesothelioma. Interact Cardiovasc Thorac Surg 10: 185-189, 2010.
9. Wendell M, Bazhenova L, Morgan A. Boisot S, Marinucci D, Luttgen M, Nieva JJ, Kuhn P and Bethel K: Circulating tumor cells (CTC) in mesothelioma and its cytomorphological and immunohistochemical correlation with the primary tumor specimens. ASCO Annual Meeting. J Clin Oncol 29, 2011
10. Tanaka F, Yoneda K, Kondo N, Hashimoto M, Takuwa T, Matsumoto S, Hasegawa S, Okumura Y, Tsujimura T, Fukuoka K and Nakano T: Circulating tumor cell (CTC) as a clinical marker in malignant pleural mesothelioma (MPM). ASCO Annual Meeting. J Clin Oncol 29, 2011.
11. Fukuoka K, Tanaka F, Tsujimura T, Hashimoto-Tamaoki T, Hasegawa S and Nakano T: Nihon exploratory study on the detection of markers for diagnosing early-stage malignant mesothelioma. Nihon Eiseigaku Zasshi 66: 553-557, 2011.
12. Mego M, Gao H, Lee BN, Cohen EN, Tin S, Giordano A, Wu Q, Liu P, Nieto Y, Champlin RE, Hortobagyi GN, Cristofanilli M, Ueno NT and Reuben JM: Prognostic Value of EMT-Circulating Tumor Cells in Metastatic Breast Cancer Patients Undergoing High-Dose Chemotherapy with Autologous Hematopoietic Stem Cell Transplantation. J Cancer 3: 369-380, 2012.
13. Kang Y and Massague J: Epithelial-mesenchymal transitions: twist in development and metastasis. Cell 118: 277-279, 2004.
14. Thiery JP: Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer 2: 442-454, 2002.
15. Schramm A, Opitz I, Thies S, Seifert B, Moch H, Weder W and Soltermann A: Prognostic significance of epithelial-mesenchymal transition in malignant pleural mesothelioma. Eur J Cardiothorac Surg 37: 566-572, 2010.
16. Kadota K, Suzuki K, Sima CS, Rusch VW, Adusumilli PS and Travis WD: Pleomorphic epithelioid diffuse malignant pleural mesothelioma: a clinicopathological review and conceptual proposal to reclassify as biphasic or sarcomatoid mesothelioma. J Thorac Oncol 6: 896-904, 2011.
17. Rusch VW and Venkatraman ES: Important prognostic factors in patients with malignant pleural mesothelioma, managed surgically. Ann Thorac Surg 68: 1799-1804, 1999.
18. Zellos LS and Sugarbaker DJ: Multimodality treatment of diffuse malignant pleural mesothelioma. Semin Oncol 29: 41-50, 2002.
19. Milano MT and Zhang H: Malignant pleural mesothelioma:A population-based study of survival. J Thorac Oncol 5: 1841-1848, 2010.
20. Voulgari A and Pintzas A: Epithelial-mesenchymal transition in cancer metastasis: mechanisms, markers and strategies to overcome drug resistance in the clinic. Biochim Biophys Acta 1796: 75-90, 2009.
21. Zeisberg M and Neilson EG: Biomarkers for epithelialme-senchymal transitions. J Clin Invest 119: 1429-1437, 2009.
22. Cates JM, Dupont WD, Barnes JW, Edmunds HS, Fasig JH, Olson SJ and Black CC: Markers of epithelial-mesenchymal transition and epithelial differentiation in sarcomatoid carcinoma: utility in the differential diagnosis with sarcoma. Appl Immunohistochem Mol Morphol 16: 251-262, 2008.
23. Tarin D, Thompson EW and Newgreen DF: The fallacy of epithelial mesenchymal transition in neoplasia. Cancer Res 65: 5996-6000, 2005.